A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Trial Profile

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Eribulin (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 16 Jun 2016 Planned End Date changed from 1 Feb 2015 to 1 Dec 2016.
    • 13 May 2016 Pooled subgroup analysis results of two phase III trials (assessing efficacy of eribulin in various subgroups; studies 301 and 305) published in the Annals of Oncology
    • 03 Jul 2014 According to an Eisai Co media release, the European Commission granted approval for an expanded indication of eribulin in the EU, which includes earlier-line treatment (first or second-line) in patients with metastatic breast cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top